Ewan R Pearson

List of Publications by Citations

136 papers	7,311 citations	37 h-index	85 g-index
148 ext. papers	9,249 ext. citations	10.4 avg, IF	6.15 L-index

#	Paper	IF	Citations
136	Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. *New England Journal of Medicine*, **2004**, 350, 1838-49	59.2	930
135	The mechanisms of action of metformin. *Diabetologia*, **2017**, 60, 1577-1585	10.3	870
134	Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. *New England Journal of Medicine*, **2006**, 355, 467-77	59.2	740
133	Genetic cause of hyperglycaemia and response to treatment in diabetes. *Lancet, The*, **2003**, 362, 1275-81	40	437
132	Metformin and the gastrointestinal tract. *Diabetologia*, **2016**, 59, 426-35	10.3	330
131	Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. *Nature Genetics*, **2011**, 43, 117-20	36.3	319
130	Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. *PLoS Medicine*, **2007**, 4, e118	11.6	279
129	Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. *Diabetes*, **2007**, 56, 2178-82	0.9	251
128	New loci associated with birth weight identify genetic links between intrauterine growth and adult height and metabolism. *Nature Genetics*, **2013**, 45, 76-82	36.3	232
127	Relapsing diabetes can result from moderately activating mutations in KCNJ11. *Human Molecular Genetics*, **2005**, 14, 925-34	5.6	165
126	Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study. *Diabetes*, **2015**, 64, 1786-93	0.9	141
125	Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. *Diabetes*, **2009**, 58, 1434-9	0.9	132
124	Systematic Population Screening, Using Biomarkers and Genetic Testing, Identifies 2.5% of the U.K. Pediatric Diabetes Population With Monogenic Diabetes. *Diabetes Care*, **2016**, 39, 1879-1888	14.6	117
123	Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. *Nature Genetics*, **2016**, 48, 1055-1059	36.3	108
122	Contrasting diabetes phenotypes associated with hepatocyte nuclear factor-1alpha and -1beta mutations. *Diabetes Care*, **2004**, 27, 1102-7	14.6	99
121	Genetic Evidence for a Link Between Favorable Adiposity and Lower Risk of Type 2 Diabetes, Hypertension, and Heart Disease. *Diabetes*, **2016**, 65, 2448-60	0.9	86
120	Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study. *Lancet Diabetes and Endocrinology,the*, **2018**, 6, 637-646	18.1	77

119	Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors. *Diabetes Care*, **2015**, 38, 323-8	14.6	76
118	Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis. *Lancet Diabetes and Endocrinology,the*, **2014**, 2, 481-7	18.1	76
117	Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*, **2020**, 43, 1617-1635	14.6	75
116	Population-Based Assessment of a Biomarker-Based Screening Pathway to Aid Diagnosis of Monogenic Diabetes in Young-Onset Patients. *Diabetes Care*, **2017**, 40, 1017-1025	14.6	73
115	A Genome-Wide Association Study of IVGTT-Based Measures of First-Phase Insulin Secretion Refines the Underlying Physiology of Type 2 Diabetes Variants. *Diabetes*, **2017**, 66, 2296-2309	0.9	69
114	Adherence to Oral Glucose-Lowering Therapies and Associations With 1-Year HbA1c: A Retrospective Cohort Analysis in a Large Primary Care Database. *Diabetes Care*, **2016**, 39, 258-263	14.6	57
113	Type 2 diabetes: a multifaceted disease. *Diabetologia*, **2019**, 62, 1107-1112	10.3	55
112	C-Peptide Decline in Type 1 Diabetes Has Two Phases: An Initial Exponential Fall and a Subsequent Stable Phase. *Diabetes Care*, **2018**, 41, 1486-1492	14.6	54
111	Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial. *Diabetes Care*, **2020**, 43, 1356-1359	14.6	48
110	Genome-Wide and Abdominal MRI Data Provide Evidence That a Genetically Determined Favorable Adiposity Phenotype Is Characterized by Lower Ectopic Liver Fat and Lower Risk of Type 2 Diabetes, Heart Disease, and Hypertension. *Diabetes*, **2019**, 68, 207-219	0.9	46
109	Clinical and genetic determinants of progression of type 2 diabetes: a DIRECT study. *Diabetes Care*, **2014**, 37, 718-724	14.6	45
108	Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. *Diabetes Care*, **2018**, 41, 1844-1853	14.6	43
107	Visit-to-Visit HbA Variability Is Associated With Cardiovascular Disease and Microvascular Complications in Patients With Newly Diagnosed Type 2 Diabetes. *Diabetes Care*, **2020**, 43, 426-432	14.6	42
106	Novel subgroups of type 2 diabetes and their association with microvascular outcomes in an Asian Indian population: a data-driven cluster analysis: the INSPIRED study. *BMJ Open Diabetes Research and Care*, **2020**, 8,	4.5	41
105	Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. *Cardiovascular Diabetology*, **2016**, 15, 97	8.7	41
104	CYP2C8 and SLCO1B1 Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes. *Diabetes Care*, **2016**, 39, 1902-1908	14.6	40
103	Using machine learning approaches for multi-omics data analysis: A review. *Biotechnology Advances*, **2021**, 49, 107739	17.8	40
102	Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium. *Diabetologia* , **2014**, 57, 1132-42	10.3	39

101	A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin. *Diabetologia*, **2018**, 61, 2520-2527	10.3	38
100	Cohort Profile: Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS). *International Journal of Epidemiology*, **2018**, 47, 380-381j	7.8	37
99	Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. *Diabetes Care*, **2018**, 41, 705-712	14.6	36
98	Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery. *Nature Reviews Endocrinology*, **2016**, 12, 337-46	15.2	36
97	Formalising recall by genotype as an efficient approach to detailed phenotyping and causal inference. *Nature Communications*, **2018**, 9, 711	17.4	35
96	Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2017**, 19, 356-363	6.7	35
95	Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010-2017. *Diabetes, Obesity and Metabolism*, **2019**, 21, 1576-1584	6.7	34
94	Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia*, **2020**, 63, 1671-1693	10.3	33
93	Acute kidney injury, plasma lactate concentrations and lactic acidosis in metformin users: A GoDarts study. *Diabetes, Obesity and Metabolism*, **2017**, 19, 1579-1586	6.7	31
92	Effect of Serotonin Transporter 5-HTTLPR Polymorphism on Gastrointestinal Intolerance to Metformin: A GoDARTS Study. *Diabetes Care*, **2016**, 39, 1896-1901	14.6	31
91	Quantifying the extent to which index event biases influence large genetic association studies. *Human Molecular Genetics*, **2017**, 26, 1018-1030	5.6	30
90	Rates of glycaemic deterioration in a real-world population with type 2 diabetes. *Diabetologia*, **2018**, 61, 607-615	10.3	26
89	Performance of Cardiovascular Disease Risk Scores in People Diagnosed With Type 2 Diabetes: External Validation Using Data From the National Scottish Diabetes Register. *Diabetes Care*, **2018**, 41, 2010-2018	14.6	26
88	A common missense variant of LILRB5 is associated with statin intolerance and myalgia. *European Heart Journal*, **2017**, 38, 3569-3575	9.5	25
87	Monogenic Diabetes: From Genetic Insights to Population-Based Precision in Care. Reflections From a EditorsRExpert Forum. *Diabetes Care*, **2020**, 43, 3117-3128	14.6	23
86	Metabolite ratios as potential biomarkers for type 2 diabetes: a DIRECT study. *Diabetologia*, **2018**, 61, 117-129	10.3	21
85	Should Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c?. *PLoS ONE*, **2016**, 11, e0152428	3.7	21
84	Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. *Diabetes Care*, **2020**, 43, 1948-1957	14.6	21

83	Sharing data for future research-engaging participantsRviews about data governance beyond the original project: a DIRECT Study. *Genetics in Medicine*, **2019**, 21, 1131-1138	8.1	21
82	Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by) and Organic Cation Transporter 1 (OCT1) (Encoded by) and Gastrointestinal Intolerance to Metformin in Type 2 Diabetes: An IMI DIRECT Study. *Diabetes Care*, **2019**, 42, 1027-1033	14.6	20
81	No differences in mortality between users of pancreatic-specific and non-pancreatic-specific sulphonylureas: a cohort analysis. *Diabetes, Obesity and Metabolism*, **2008**, 10, 350-2	6.7	20
80	A Type 1 Diabetes Genetic Risk Score Can Identify Patients With GAD65 Autoantibody-Positive Type 2 Diabetes Who Rapidly Progress to Insulin Therapy. *Diabetes Care*, **2019**, 42, 208-214	14.6	20
79	Development and validation of multivariable clinical diagnostic models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 18-50 years. *BMJ Open*, **2019**, 9, e031586	3	19
78	Diabetes: Is There a Future for Pharmacogenomics Guided Treatment?. *Clinical Pharmacology and Therapeutics*, **2019**, 106, 329-337	6.1	18
77	Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts. *PLoS Medicine*, **2020**, 17, e1003149	11.6	18
76	Genetic Variants in and Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes. *Diabetes*, **2018**, 67, 1428-1440	0.9	18
75	Interaction between variants in the CYP2C9 and POR genes and the risk of sulfonylurea-induced hypoglycaemia: A GoDARTS Study. *Diabetes, Obesity and Metabolism*, **2018**, 20, 211-214	6.7	18
74	Zinc transport and diabetes risk. *Nature Genetics*, **2014**, 46, 323-4	36.3	15
73	Obesity, clinical, and genetic predictors for glycemic progression in Chinese patients with type 2 diabetes: A cohort study using the Hong Kong Diabetes Register and Hong Kong Diabetes Biobank. *PLoS Medicine*, **2020**, 17, e1003209	11.6	15
72	Zinc Transporter 8 Autoantibodies (ZnT8A) and a Type 1 Diabetes Genetic Risk Score Can Exclude Individuals With Type 1 Diabetes From Inappropriate Genetic Testing for Monogenic Diabetes. *Diabetes Care*, **2019**, 42, e16-e17	14.6	15
71	The Relationship between AKI and CKD in Patients with Type 2 Diabetes: An Observational Cohort Study. *Journal of the American Society of Nephrology: JASN*, **2021**, 32, 138-150	12.7	15
70	Motivations for data sharing-views of research participants from four European countries: A DIRECT study. *European Journal of Human Genetics*, **2019**, 27, 721-729	5.3	14
69	Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium. *Diabetologia*, **2019**, 62, 1601-1615	10.3	14
68	Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. *BMJ Open Diabetes Research and Care*, **2020**, 8,	4.5	14
67	Defining drug response for stratified medicine. *Drug Discovery Today*, **2017**, 22, 173-179	8.8	13
66	Metformin increases fasting glucose clearance and endogenous glucose production in non-diabetic individuals. *Diabetologia*, **2020**, 63, 444-447	10.3	13

65	Pharmacogenetics and future strategies in treating hyperglycaemia in diabetes. *Frontiers in Bioscience - Landmark*, **2009**, 14, 4348-62	2.8	12
64	Replication and cross-validation of type 2 diabetes subtypes based on clinical variables: an IMI-RHAPSODY study. *Diabetologia*, **2021**, 64, 1982-1989	10.3	11
63	Genetic studies of abdominal MRI data identify genes regulating hepcidin as major determinants of liver iron concentration. *Journal of Hepatology*, **2019**, 71, 594-602	13.4	10
62	Predicting glycated hemoglobin levels in the non-diabetic general population: Development and validation of the DIRECT-DETECT prediction model - a DIRECT study. *PLoS ONE*, **2017**, 12, e0171816	3.7	10
61	Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study. *Diabetes Care*, **2020**, 43, 2493-2499	14.6	10
60	Pharmacogenetics and target identification in diabetes. *Current Opinion in Genetics and Development*, **2018**, 50, 68-73	4.9	8
59	Costs and Treatment Pathways for Type 2 Diabetes in the UK: A Mastermind Cohort Study. *Diabetes Therapy*, **2017**, 8, 1031-1045	3.6	8
58	Evaluating associations between the benefits and risks of drug therapy in type 2 diabetes: a joint modeling approach. *Clinical Epidemiology*, **2018**, 10, 1869-1877	5.9	8
57	Statistical power considerations in genotype-based recall randomized controlled trials. *Scientific Reports*, **2016**, 6, 37307	4.9	7
56	What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study. *BMC Medicine*, **2019**, 17, 79	11.4	6
55	Dissecting the Etiology of Type 2 Diabetes in the Pima Indian Population. *Diabetes*, **2015**, 64, 3993-5	0.9	6
54	Processes Underlying Glycemic Deterioration in Type 2 Diabetes: An IMI DIRECT Study. *Diabetes Care*, **2021**, 44, 511-518	14.6	6
53	Integrative network analysis highlights biological processes underlying GLP-1 stimulated insulin secretion: A DIRECT study. *PLoS ONE*, **2018**, 13, e0189886	3.7	5
52	Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. *Diabetes Care*, **2021**, 44, 2673-2682	14.6	5
51	Reflections on the sulphonylurea story: A drug class at risk of extinction or a drug class worth reviving?. *Diabetes, Obesity and Metabolism*, **2019**, 21, 761-771	6.7	5
50	Strategies to identify individuals with monogenic diabetes: results of an economic evaluation. *BMJ Open*, **2020**, 10, e034716	3	5
49	A Polygenic Score for Type 2 Diabetes Risk Is Associated With Both the Acute and Sustained Response to Sulfonylureas. *Diabetes*, **2021**, 70, 293-300	0.9	5
48	The governance structure for data access in the DIRECT consortium: an innovative medicines initiative (IMI) project. *Life Sciences, Society and Policy*, **2018**, 14, 20	3.2	5

47	The role of physical activity in metabolic homeostasis before and after the onset of type 2 diabetes: an IMI DIRECT study. *Diabetologia*, **2020**, 63, 744-756	10.3	4
46	Quantitative MRI evaluation of whole abdomen adipose tissue volumes in healthy volunteers-validation of technique and implications for clinical studies. *British Journal of Radiology*, **2018**, 91, 20180025	3.4	4
45	Evidence-based prioritisation and enrichment of genes interacting with metformin in type 2 diabetes. *Diabetologia*, **2017**, 60, 2231-2239	10.3	4
44	Profiles of Glucose Metabolism in Different Prediabetes Phenotypes, Classified by Fasting Glycemia, 2-Hour OGTT, Glycated Hemoglobin, and 1-Hour OGTT: An IMI DIRECT Study. *Diabetes*, **2021**, 70, 2092-2106	0.9	4
43	Distinct Molecular Signatures of Clinical Clusters in People With Type 2 Diabetes: An IMI-RHAPSODY Study. *Diabetes*, **2021**, 70, 2683-2693	0.9	4
42	The search for predictive metabolic biomarkers for incident T2DM. *Nature Reviews Endocrinology*, **2018**, 14, 444-446	15.2	3
41	Circulating Tissue Factor-Positive Procoagulant Microparticles in Patients with Type 1 Diabetes. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, **2019**, 12, 2819-2828	3.4	3
40	Whole blood co-expression modules associate with metabolic traits and type 2 diabetes: an IMI-DIRECT study. *Genome Medicine*, **2020**, 12, 109	14.4	3
39	Young-onset diabetes in Asian Indians is associated with lower measured and genetically determined beta cell function.. *Diabetologia*, **2022**, 1	10.3	3
38	Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes.. *Nature Medicine*, **2022**, 28, 982-988	50.5	3
37	Genetic Risk of Diverticular Disease Predicts Early Stoppage of Nicorandil. *Clinical Pharmacology and Therapeutics*, **2020**, 108, 1171-1175	6.1	2
36	Glu83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia. *Circulation: Cardiovascular Genetics*, **2017**, 10,		2
35	Post-load glucose subgroups and associated metabolic traits in individuals with type 2 diabetes: An IMI-DIRECT study. *PLoS ONE*, **2020**, 15, e0242360	3.7	2
34	Elevated circulating follistatin associates with an increased risk of type 2 diabetes. *Nature Communications*, **2021**, 12, 6486	17.4	2
33	Predicting post one-year durability of glucose-lowering monotherapies in patients with newly-diagnosed type 2 diabetes mellitus - A MASTERMIND precision medicine approach (UKPDS 87). *Diabetes Research and Clinical Practice*, **2020**, 166, 108333	7.4	2
32	Dietary metabolite profiling brings new insight into the relationship between nutrition and metabolic risk: An IMI DIRECT study. *EBioMedicine*, **2020**, 58, 102932	8.8	2
31	Interaction between Omeprazole and Gliclazide in Relation to CYP2C19 Phenotype. *Journal of Personalized Medicine*, **2021**, 11,	3.6	2
30	Cohort profile: DOLORisk Dundee: a longitudinal study of chronic neuropathic pain. *BMJ Open*, **2021**, 11, e042887	3	2

29	The role of genetics in fetal programming of adult cardiometabolic disease. *Journal of Developmental Origins of Health and Disease*, **2021**, 1-8	2.4	2
28	Genome-Wide Association Analysis of Pancreatic Beta-Cell Glucose Sensitivity. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, 80-90	5.6	2
27	4th ESPT Conference: pharmacogenomics and personalized medicine research progress and clinical implementation. *Pharmacogenomics*, **2019**, 20, 1063-1069	2.6	1
26	Four groups of type 2 diabetes contribute to the etiological and clinical heterogeneity in newly diagnosed individuals: An IMI DIRECT study.. *Cell Reports Medicine*, **2022**, 3, 100477	18	1
25	Derivation and validation of a type 2 diabetes treatment selection algorithm for SGLT2-inhibitor and DPP4-inhibitor therapies based on glucose-lowering efficacy: cohort study using trial and routine clinical data		1
24	Dorothy Hodgkin Lecture 2021: Drugs, genes and diabetes. *Diabetic Medicine*, **2021**, 38, e14726	3.5	1
23	Replication and cross-validation of T2D subtypes based on clinical variables: an IMI-RHAPSODY study		1
22	In a cohort of individuals with type 2 diabetes using the drug sulfasalazine, HbA lowering is associated with haematological changes. *Diabetic Medicine*, **2021**, 38, e14463	3.5	1
21	Genetic analysis of blood molecular phenotypes reveals regulatory networks affecting complex traits: a DIRECT study		1
20	The Impact of Low-dose Gliclazide on the Incretin Effect and Indices of Beta-cell Function. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, 2036-2046	5.6	1
19	Young onset diabetes in Asian Indians is associated with lower measured and genetically determined beta-cell function: an INSPIRED study		1
18	A roadmap to achieve pharmacological precision medicine in diabetes. *Diabetologia*,	10.3	1
17	The impact of birthweight on subsequent phenotype of type 2 diabetes in later life.. *Diabetic Medicine*, **2022**, e14792	3.5	0
16	Association of Genetic Variant at Chromosome 12q23.1 With Neuropathic Pain Susceptibility. *JAMA Network Open*, **2021**, 4, e2136560	10.4	0
15	Reducing Glut2 throughout the body does not result in cognitive behaviour differences in aged male mice. *BMC Research Notes*, **2020**, 13, 438	2.3	0
14	Polymorphism in Locus Modifies Risk of Atrial Fibrillation in Patients on Thyroid Hormone Replacement Therapy. *Frontiers in Genetics*, **2021**, 12, 652878	4.5	0
13	Utilizing Large Electronic Medical Record Data Sets to Identify Novel Drug-Gene Interactions for Commonly Used Drugs. *Clinical Pharmacology and Therapeutics*, **2021**, 110, 816-825	6.1	0
12	Evidence of a Causal Relationship between Serum Thyroid-Stimulating Hormone and Osteoporotic Bone Fractures.. *European Thyroid Journal*, **2021**, 10, 439-446	4.2	0

11	PS7 - 3. Predicting Glycated Haemoglobin in the Non-Diabetic General Population: a DIRECT Study. *Nederlands Tijdschrift Voor Diabetologie*, **2013**, 11, 154-154	0
10	Response to Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948-1957. *Diabetes Care*, **2020**, 43, e202-e203	14.6
9	Crossover studies can help the individualisation of care in type 2 diabetes: the MASTERMIND approach. *Practical Diabetes*, **2016**, 33, 115-117	0.7
8	The genetic association of the transcription factor NPAT with glycemic response to metformin involves regulation of fuel selection. *PLoS ONE*, **2021**, 16, e0253533	3.7
7	Response to Comment on Dawed et al. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care 2021;44:2673-2682.. *Diabetes Care*, **2022**, 45, e82-e83	14.6
6	Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts **2020**, 17, e1003149	
5	Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts **2020**, 17, e1003149	
4	Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts **2020**, 17, e1003149	
3	Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts **2020**, 17, e1003149	
2	Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts **2020**, 17, e1003149	
1	Precision Medicine in Diabetes. *Handbook of Experimental Pharmacology*, **2022**,	3.2